Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
CVKDPONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market.
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CVKDPONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
CVKDPONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis
Cadrenal Therapeutics Highlights Tecarfarin As Safer Anticoagulant Alternative For High-Risk LVAD Patients
CVKDCadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
CVKDPONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #cadrenaltherapeutics--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
CVKDPONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #cadrenaltherapeutics--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.
HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $32 Price Target
CVKDCadrenal Therapeutics Announces Manufacturing And Supply Chain Milestones For Tecarfarin, Oral VKA Anticoagulant Designed To Address Unmet Needs In Anticoagulation Therapy
CVKDCadrenal Therapeutics Q1 EPS $(2.09) Misses $(1.25) Estimate
CVKDCadrenal Therapeutics FY 2024 GAAP EPS $(8.73) Misses $(7.59) Estimate
CVKD12 Health Care Stocks Moving In Monday's After-Market Session
CVKD